Healthcare
Partners
ORYZON announces First Patient In in FRIDA, a Phase Ib trial with iadademstat in relapsed/...
Healthcare
Acceso a la innovación
Primary objectives: to assess safety, tolerability and RP2D
Partners
ORYZON announces clinical candidate nomination of ORY-4001 for the treatment of CNS disord...
Healthcare
Acceso a la innovación
Corporate
Rescues motor-neuronal deficiencies in a Charcot-Marie-Tooth model